Vectus Biosystems

Vectus Biosystems Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Vectus Biosystems (VBS.AX) as of Nov 5, 2026 is -36.79 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 46.71 % — a change of -178.76% (lower).

Cash Conversion

-36.79 %

YoY

-178.76%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Vectus Biosystems is 2026 -36.79 % . Cash Conversion Rate (OCF/Net Income) of Vectus Biosystems was 2025 46.71 % . It decreases by -178.76% lower compared to the previous year.

The Vectus Biosystems Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2019
65.19 AUD
Jan 1, 2020
100.18 AUD
Jan 1, 2021
84.31 AUD
Jan 1, 2022
111.20 AUD
Jan 1, 2023
68.22 AUD
Jan 1, 2024
86.94 AUD
Jan 1, 2025
46.71 AUD
Jan 1, 2026
-36.79 AUD
The Vectus Biosystems Cash Conversion history
YEARCash ConversionYoY
-36.79 %-178.76%
46.71 %-46.28%
86.94 %+27.45%
68.22 %-38.66%
111.20 %+31.89%
84.31 %-15.84%
100.18 %+53.68%
65.19 %+21.60%
53.61 %-47.75%
102.60 %+26.20%
81.30 %-17.96%
99.10 %+13.55%
87.27 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vectus Biosystems Stock analysis

What does Vectus Biosystems do? Vectus Biosystems Ltd. generates revenue through the development and commercialization of pharmaceutical products targeting fibrotic diseases and hypertension. The company focuses on VB0004, a compound designed to treat tissue hardening and high blood pressure, alongside candidates for fibrotic liver conditions like NASH and pulmonary fibrosis. Its subsidiary Accugen Pty Limited offers the Accugen platform, which provides qPCR reagents and software for accurate DNA and RNA quantification in laboratory testing. The primary buyers of these products are pharmaceutical companies and research institutions seeking advanced drug development tools and therapies for fibrotic disorders. Vectus Biosystems targets the medical research and development sector, specifically addressing unmet needs in fibrotic disease treatment. The Accugen platform serves laboratories requiring efficient molecular analysis tools, with its technology enhancing the speed and precision of qPCR testing. The company’s revenue streams are derived from both therapeutic product development and the sale of diagnostic solutions to biotech firms and academic research entities. The firm’s focus on fibrosis-related treatments, including heart, kidney, and liver diseases, positions it within niche therapeutic segments. Accugen’s reagents and software are sold to laboratories as part of the qPCR workflow, supporting drug discovery processes. Pharmaceutical companies and research organizations are the key segments purchasing Vectus Biosystems’ products for their R&D pipelines and clinical applications. Vectus Biosystems is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vectus Biosystems stock

Cash Conversion Rate (OCF/Net Income) of Vectus Biosystems is -36.79 % in 2026.

Cash Conversion Rate (OCF/Net Income) of Vectus Biosystems changed from 46.71 % to -36.79 %, representing a -178.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Vectus Biosystems since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Vectus Biosystems with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Vectus Biosystems

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Vectus Biosystems